Hemogenyx Pharmaceuticals PLC (HEMO) - Total Assets
Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) holds total assets worth GBX3.10 Million GBX (≈ $377.33 USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hemogenyx Pharmaceuticals PLC - Total Assets Trend (2014–2024)
This chart illustrates how Hemogenyx Pharmaceuticals PLC's total assets have evolved over time, based on quarterly financial data. Also see Hemogenyx Pharmaceuticals PLC stock valuation for the company's overall valuation and market capitalisation.
Hemogenyx Pharmaceuticals PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Hemogenyx Pharmaceuticals PLC's total assets of GBX3.10 Million consist of 19.9% current assets and 80.1% non-current assets. Review HEMO total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 3.8% |
| Accounts Receivable | GBX7.86K | 0.2% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX477.40K | 11.3% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Hemogenyx Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hemogenyx Pharmaceuticals PLC stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hemogenyx Pharmaceuticals PLC's current assets represent 19.9% of total assets in 2024, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 14.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Hemogenyx Pharmaceuticals PLC Competitors by Total Assets
Key competitors of Hemogenyx Pharmaceuticals PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Hemogenyx Pharmaceuticals PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.43 | 4.38 | 15.75 |
| Quick Ratio | 0.43 | 5.85 | 15.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-752.98K | GBX1.91 Million | GBX3.18 Million |
Hemogenyx Pharmaceuticals PLC - Advanced Valuation Insights
This section examines the relationship between Hemogenyx Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 69.44 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -31.0% |
| Total Assets | GBX4.21 Million |
| Market Capitalization | $306.59K USD |
Valuation Analysis
Below Book Valuation: The market values Hemogenyx Pharmaceuticals PLC's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hemogenyx Pharmaceuticals PLC's assets decreased by 31.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hemogenyx Pharmaceuticals PLC (2014–2024)
The table below shows the annual total assets of Hemogenyx Pharmaceuticals PLC from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX4.21 Million ≈ $512.43 |
-31.02% |
| 2023-12-31 | GBX6.11 Million ≈ $742.91 |
-13.91% |
| 2022-12-31 | GBX7.09 Million ≈ $862.97 |
-16.76% |
| 2021-12-31 | GBX8.52 Million ≈ $1.04K |
+219.77% |
| 2020-12-31 | GBX2.66 Million ≈ $324.20 |
+153.79% |
| 2019-12-31 | GBX1.05 Million ≈ $127.74 |
-54.34% |
| 2018-12-31 | GBX2.30 Million ≈ $279.79 |
-4.01% |
| 2017-12-31 | GBX2.40 Million ≈ $291.47 |
+128.71% |
| 2016-12-31 | GBX1.05 Million ≈ $127.44 |
+222.62% |
| 2015-12-31 | GBX324.65K ≈ $39.50 |
+642.40% |
| 2015-02-28 | GBX43.73K ≈ $5.32 |
0.00% |
| 2014-12-31 | GBX43.73K ≈ $5.32 |
-- |
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more